SigTuple develops smart robotic microscopes and AI software for automating clinical laboratory workflows, with its flagship product AI100 focused on digital haematology. The company has concentrated on AI100 since 2020 and counts major diagnostics players among its customers. AI100 received US FDA 510(k) clearance in September 2023, making SigTuple the first Indian company and the third worldwide to secure FDA clearance for AI-assisted digital haematology. SigTuple uses Horiba Medical as a distribution channel in South Asia and has expanded into Southeast Asia, the Middle East, and North Africa, with plans to enter Europe and the Americas. The company will use the new funding to support regulatory clearances, broaden its product offering, and accelerate geographic expansion. To date the company has raised more than $40 million and is gaining significant traction in the Indian market. SigTuple develops AI and digitization solutions for pathology, primarily automating analysis of peripheral blood smears and urine samples and offering the product AI100 in India. The company says it is expanding its AI suite toward Hematology, Cytology, and Microbiology to become a one‑stop shop for lab AI. Over the past 12 months SigTuple reports major product improvements, new product additions, stronger customer traction, and beefed up channel partners. It has forged partnerships with large diagnostic chains and hospitals including HCG Hospitals, Krsnaa Diagnostics, and Thyrocare Technologies. Management plans to use new capital to drive geographical expansion, broaden the product portfolio, and support regulatory clearances. The CEO, Tathagato Rai Dastidar, stated that 2023 is the year SigTuple will go global with expansions planned across SEA, MENA, North America, and Europe. SigTuple is a diagnostics startup based in India. The company announced it secured a $16-million Series C round. The Series C was led by Trusted Insight. Existing investors Accel Partners, Chiratae Ventures and Pi Ventures participated in the round. Flipkart co-founder Binny Bansal also participated and will join SigTuple's board as part of the agreement. The company made the announcement on Monday; no further operational or financial details were provided in the article. SigTuple develops AI and machine-learning solutions to analyze vital biological samples and assist diagnosis, and it also produces low-cost smart hardware for pathological analysis. The company emphasizes making diagnostics more accessible, affordable and accurate through smart technology. With the latest funding, SigTuple plans to expand distribution, conduct additional R&D, and broaden deployment of its solutions across markets in India. Investors and company leadership frame its work as part of a broader big-data driven shift in healthcare delivery. Financially, SigTuple announced a $19 million Series B that brings its total capital raised to nearly $25 million. Prior financings included a Series A in February 2017 and a seed round in 2015. SigTuple Technologies Pvt. Ltd. is a Bengaluru-based health technology startup. The article reports the company raised $5.8 million in a Series A round. The round was led by existing investor Accel Partners. The company announced the funding in a statement on Monday. No further details on product offerings, use of proceeds, other investors, or operating metrics were disclosed in the article. The firm is structured as a private limited company (Pvt. Ltd.).

Total raised

$49M

Funding rounds

6

Latest round

Series C

Latest activity

Aug 2024